Can't remember if the AG pathway existed when the drug importation legislation was first floated.
The AG pathway has existed ever since Hatch-Waxman was enacted in 1984; however, it took drug companies a couple of decades to discover that they could exploit it.
It also depends on how much cheaper EU lovenox is. Anyone know? If it's not >20% cheaper than generic US lovenox, maybe not much of a problem.
There is no such thing as an EU price per se; rather, the price of Lovenox (and all other drugs) varies considerably within Europe from country to country. (This gives rise to an intra-EU diversion business by drug distributors, but that’s not our problem.) On average, the price of Lovenox is Europe is probably less than half the US price.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”